#USA #Los Angeles #Schall Law Firm #Securities Law #Grace Therapeutics

Investigation of Grace Therapeutics, Inc.

Introduction

In a significant development for investors, the Schall Law Firm, known for its advocacy in shareholder rights, has launched an investigation into Grace Therapeutics, Inc. (NASDAQ: GRCE). This inquiry is rooted in concerns over potential violations of securities laws that may have adversely impacted shareholders of the company.

Background

The essence of the investigation stems from alarming news relayed by Grace Therapeutics on April 23, 2026, which announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) concerning the company's New Drug Application (NDA) for GTx-104, a treatment aimed at patients with aneurysmal Subarachnoid Hemorrhage (aSAH). The implications of this announcement were dire.

Specifically, the FDA's letter cited various deficiencies related to the application's Chemistry, Manufacturing, and Controls (CMC) as well as issues in non-clinical product toxicology assessments and product manufacturing shortcomings at their contract manufacturing organizations. As a direct consequence of this negative assessment, the stock of Grace saw a staggering decline, plummeting almost 45.5% on the same day.

Investor Implications

The fallout from this situation has raised critical questions about the disclosures made by Grace Therapeutics leading up to this point. Investors may find themselves questioning whether the leadership misrepresented the company’s stability or omitted crucial information from the market, thus infringing upon their rights.

Schall Law Firm is reaching out to affected investors who believe they have sustained losses due to these events. The firm is actively encouraging those shareholders to join the ongoing investigation. Individuals interested in participating can easily connect with the firm to discuss their cases and explore their rights without any financial obligation.

How to Participate

If you are among those who held shares of Grace Therapeutics and were negatively impacted, the Schall Law Firm is eager to hear from you. They provide an avenue for investors seeking justice and possible compensation for losses incurred.

Investors are advised to contact Brian Schall directly at the Schall Law Firm’s offices located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067 or reach him at 310-301-3335 for a complimentary consultation. Additionally, interested parties can visit the firm’s official website at www.schallfirm.com or send an email request to the provided address.

Conclusion

The potential implications of the investigations led by the Schall Law Firm could resonate far beyond individual shareholder claims. They could prompt deeper scrutiny into corporate governance and transparency practices within the pharmaceutical sector. As developments continue to unfold, affected investors remain hopeful for accountability and resolutions that address the recent turmoil.

In a climate where shareholder trust is paramount, this situation serves as a pertinent reminder that vigilance and advocacy are critical in safeguarding investors' rights against corporate discrepancies.